Literature DB >> 21501606

Hes6 is required for actin cytoskeletal organization in differentiating C2C12 myoblasts.

Caroline M P Malone1, Renae Domaschenz, Yoko Amagase, Ian Dunham, Kasumi Murai, Philip H Jones.   

Abstract

Hes6 is a member of the hairy-enhancer-of-split family of transcription factors that regulate proliferating cell fate in development and is known to be expressed in developing muscle. Here we investigate its function in myogenesis in vitro. We show that Hes6 is a direct transcriptional target of the myogenic transcription factors MyoD and Myf5, indicating that it is integral to the myogenic transcriptional program. The localization of Hes6 protein changes during differentiation, becoming predominantly nuclear. Knockdown of Hes6 mRNA levels by siRNA has no effect on cell cycle exit or induction of myosin heavy chain expression in differentiating C2C12 myoblasts, but F-actin filament formation is disrupted and both cell motility and myoblast fusion are reduced. The knockdown phenotype is rescued by expression of Hes6 cDNA resistant to siRNA. These results define a novel role for Hes6 in actin cytoskeletal dynamics in post mitotic myoblasts.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21501606     DOI: 10.1016/j.yexcr.2011.03.023

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  8 in total

1.  Cluster analysis reveals differential transcript profiles associated with resistance training-induced human skeletal muscle hypertrophy.

Authors:  Anna Thalacker-Mercer; Michael Stec; Xiangqin Cui; James Cross; Samuel Windham; Marcas Bamman
Journal:  Physiol Genomics       Date:  2013-04-30       Impact factor: 3.107

2.  Altered expression of small heterodimer partner governs cytochrome P450 (CYP) 2D6 induction during pregnancy in CYP2D6-humanized mice.

Authors:  Kwi Hye Koh; Xian Pan; Hong-Wu Shen; Samuel L M Arnold; Ai-Ming Yu; Frank J Gonzalez; Nina Isoherranen; Hyunyoung Jeong
Journal:  J Biol Chem       Date:  2013-12-06       Impact factor: 5.157

Review 3.  Recent advances in understanding the role of HES6 in cancers.

Authors:  Imène Krossa; Thomas Strub; Arnaud Martel; Sacha Nahon-Esteve; Sandra Lassalle; Paul Hofman; Stéphanie Baillif; Robert Ballotti; Corine Bertolotto
Journal:  Theranostics       Date:  2022-05-20       Impact factor: 11.600

4.  HES6 promotes prostate cancer aggressiveness independently of Notch signalling.

Authors:  Filipe L F Carvalho; Luigi Marchionni; Anuj Gupta; Basheer A Kummangal; Edward M Schaeffer; Ashley E Ross; David M Berman
Journal:  J Cell Mol Med       Date:  2015-04-12       Impact factor: 5.310

Review 5.  Drosophila Protein Kinase CK2: Genetics, Regulatory Complexity and Emerging Roles during Development.

Authors:  Mohna Bandyopadhyay; Scott Arbet; Clifton P Bishop; Ashok P Bidwai
Journal:  Pharmaceuticals (Basel)       Date:  2016-12-29

6.  Intramuscular preadipocytes impede differentiation and promote lipid deposition of muscle satellite cells in chickens.

Authors:  Liping Guo; Huanxian Cui; Guiping Zhao; Ranran Liu; Qinghe Li; Maiqing Zheng; Yuming Guo; Jie Wen
Journal:  BMC Genomics       Date:  2018-11-26       Impact factor: 3.969

7.  Overexpression of HES6 has prognostic value and promotes metastasis via the Wnt/β-catenin signaling pathway in colorectal cancer.

Authors:  Yuandong Xu; Xuejuan Liu; Huizhong Zhang; Ziyuan Zhu; Xianqiu Wu; Xiaobing Wu; Shuling Li; Libing Song; Xuehu Xu
Journal:  Oncol Rep       Date:  2018-07-02       Impact factor: 3.906

8.  HES6 drives a critical AR transcriptional programme to induce castration-resistant prostate cancer through activation of an E2F1-mediated cell cycle network.

Authors:  Antonio Ramos-Montoya; Alastair D Lamb; Roslin Russell; Thomas Carroll; Sarah Jurmeister; Nuria Galeano-Dalmau; Charlie E Massie; Joan Boren; Helene Bon; Vasiliki Theodorou; Maria Vias; Greg L Shaw; Naomi L Sharma; Helen Ross-Adams; Helen E Scott; Sarah L Vowler; William J Howat; Anne Y Warren; Richard F Wooster; Ian G Mills; David E Neal
Journal:  EMBO Mol Med       Date:  2014-05       Impact factor: 12.137

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.